Question arises on the existence of ex post facto drug management system

Published: 2002-11-26 06:59:00

Updated: 2002-11-26 06:59:00

Pharmaceutical business sources say that in parallel with the impending implementation of a new drug price re-evaluation system, the Korea Pharmaceutical Manufacturers Association (KPMA) will call for the government to abolish the current ex post facto drug management that appears to be no longer...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK